Bamco Inc. NY grew its stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 6.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,906,520 shares of the company's stock after acquiring an additional 113,869 shares during the quarter. Bamco Inc. NY owned about 1.91% of Zai Lab worth $46,023,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in ZLAB. Swedbank AB bought a new stake in shares of Zai Lab during the 1st quarter valued at about $244,000. DCF Advisers LLC purchased a new position in shares of Zai Lab in the second quarter worth approximately $528,000. Hennion & Walsh Asset Management Inc. grew its position in Zai Lab by 14.6% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 142,189 shares of the company's stock valued at $3,432,000 after buying an additional 18,093 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Zai Lab by 26.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company's stock valued at $14,584,000 after buying an additional 125,532 shares during the last quarter. Finally, Algert Global LLC bought a new position in Zai Lab in the third quarter worth approximately $1,666,000. 41.65% of the stock is currently owned by institutional investors.
Zai Lab Stock Performance
Shares of NASDAQ ZLAB traded up $0.96 during midday trading on Tuesday, reaching $30.16. The stock had a trading volume of 1,044,510 shares, compared to its average volume of 718,701. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $36.60. The stock has a 50-day moving average of $27.64 and a 200-day moving average of $21.86. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of -10.89 and a beta of 0.99.
Analysts Set New Price Targets
ZLAB has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of Zai Lab from $38.00 to $44.00 and gave the company an "overweight" rating in a research report on Monday, October 21st. Cantor Fitzgerald reissued an "overweight" rating on shares of Zai Lab in a report on Friday, October 25th.
Read Our Latest Research Report on ZLAB
Zai Lab Company Profile
(
Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Read More
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
